High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Title | High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. |
Publication Type | Journal Article |
Year of Publication | 2011 |
Authors | Eaton, J. E., Silveira M. G., Pardi D. S., Sinakos E., Kowdley K. V., Luketic V. A. C., M Harrison E., McCashland T., Befeler A. S., Harnois D., Jorgensen R., Petz J., & Lindor K. D. |
Journal | Am J Gastroenterol |
Volume | 106 |
Issue | 9 |
Pagination | 1638-45 |
Date Published | 2011 Sep |
ISSN | 1572-0241 |
Keywords | Adolescent, Adult, Aged, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Sclerosing, Colitis, Ulcerative, Colorectal Neoplasms, Female, Follow-Up Studies, Humans, Lithocholic Acid, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk, Ursodeoxycholic Acid, Young Adult |
Abstract | OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC. |
DOI | 10.1038/ajg.2011.156 |
Alternate Journal | Am J Gastroenterol |
PubMed ID | 21556038 |
PubMed Central ID | PMC3168684 |
Grant List | M01 RR000065 / RR / NCRR NIH HHS / United States R01 DK056924-10 / DK / NIDDK NIH HHS / United States M01RR000065 / RR / NCRR NIH HHS / United States |